La vendita allo scoperto per ProQR Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di ProQR Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

ProQR Therapeutics (NASDAQ:PRQR) Azioni, Report sulle vendite allo scoperto

ProQR Therapeutics

ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.

ProQR Therapeutics N.V. - Ordinary Shares

ProQR Therapeutics NV

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Citigroup analyst Renata Cabral upgraded the rating for Coca-Cola FEMSA, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOF#NYSE">KOF</a>) from Neutral to Buy and raised the price target from $93 to $102. Coca-Cola Femsa shares closed at $84.40 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Janney Montgomery Scott analyst Sean Milligan upgraded the rating for First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) from Neutral to Buy and announced a $260 price target. First Solar shares closed at $205.03 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Julien Dormois upgraded Koninklijke Philips N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) from Underperform to Hold. Philips shares closed at $26.62 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Steven Seedhouse upgraded ProQR Therapeutics N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) from Outperform to Strong Buy and boosted the price target from $6 to $14. ProQR Therapeutics shares closed at $3.31 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Adam Seiden upgraded the rating for Summit Materials, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) from Equal-Weight to Overweight and raised the price target from $45 to $52. Summit Materials shares closed at $45.63 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying FSLR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="534" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29094905/image-301-1024x534.png" alt="" class="wp-image-619521" style="width:617px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29094905/image-301-1024x534.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29094905/image-301-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29094905/image-301-768x401.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29094905/image-301.png 1217w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41598310/jim-cramer-avoid-this-consumer-cyclical-stock-buy-lam-research">Jim Cramer: &#8216;Avoid&#8217; This Consumer Cyclical Stock, Buy Lam Research</a></li>
</ul>

News

Upgrades

Markets

Analyst Ratings

Trading Ideas

FSLR

PRQR

This First Solar Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Raymond James analyst Steven Seedhouse upgrades ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) from Outperform to Strong Buy and raises the price target from $6 to $14.

Price Target

Raymond James Upgrades ProQR Therapeutics to Strong Buy, Raises Price Target to $14

Reported Earlier, ProQR Secures $75M Through Public Offering And Private Placement With Strategic Partner Eli Lilly

All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional&nbsp;15%&nbsp;of the offering amount in ordinary shares at the public offering price, less underwriting discounts and commissions.
ProQR intends to use the net proceeds from the Offering, together with its existing cash and cash equivalents, to primarily fund research and development and clinical development to support the advancement of its current or future product candidates and the expansion of its research and development programs, and the remainder for working capital, capital expenditures and other general corporate purposes.

Offerings

ProQR Therapeutics Commences Public Offering Of Its Ordinary Shares; No Terms Disclosed

U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining around 100 points on Thursday.
Shares of CSX Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) fell sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/news/earnings/24/10/41369567/csx-stock-falls-after-worse-than-expected-q3-results-details">third-quarter earnings below analyst estimates.</a>
CSX reported quarterly GAAP earnings of 46 cents per share, which missed the consensus estimate of 48 cents per share. Quarterly revenue came in at $3.62 billion, also missing the consensus estimate of $3.676 billion. The company said its total volume of 1.59 million units for the quarter was 3% higher as compared to the third quarter of 2023.
CSX shares dipped 5.4% to $33.55 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>ProQR Therapeutics N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) shares dipped 16.2% to $3.37 in pre-market trading after surging 122% on Wednesday.</li>
<li>Lucid Group, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) declined 14.6% to $2.80 in pre-market trading after the company announced a public offering of common stock, along with a corresponding investment by an affiliate of the Public Investment Fund.</li>
<li>Lilium N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILM#NASDAQ">LILM</a>) shares fell 13.2% to $0.6350 in pre-market trading.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) shares fell 10.6% to $18.33 in pre-market trading. The company commenced its public offering of common stock.</li>
<li>Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) shares fell 8.8% to $1.64 in pre-market trading after the company provided updates on its INTERCEPT red blood cell programs in the US and Europe.</li>
<li>KE Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NASDAQ">BEKE</a>) shares declined 7.7% to $20.23 in pre-market trading after gaining around 5% on Wednesday.</li>
<li>MINISO Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NASDAQ">MNSO</a>) shares fell 6.4% to $15.41 in pre-market trading.</li>
<li>Nokia Oyj (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) shares fell 5.4% to $4.22 in pre-market trading following downbeat third-quarter results. </li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41366043/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

Pre-Market Outlook

Movers

BEKE

CAPR

CERS

LCID

LILM

MNSO

CSX Posts Weak Earnings, Joins Lucid Group, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Shares of Taiwan Semiconductor Manufacturing Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) rose sharply in today's pre-market trading following <a href="https://www.benzinga.com/news/earnings/24/10/41373163/nvidia-supplier-tsmc-reports-q3-revenue-earnings-beat-amid-rising-demand-for-ai-chips">better-than-expected quarterly results.</a>
TSMC reported consolidated third-quarter revenue of NT$759.69 billion ($23.50 billion), up 39% year-over-year. Sequentially, the top line expanded by 12.8%. In dollar terms, the revenue growth was 36% year-over-year and 12.9% quarter-over-quarter. Revenue topped the NT$748 billion consensus, as provided by Bloomberg.
Taiwan Semiconductor Manufacturing shares jumped 8.1% to $202.75 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Staffing 360 Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) rose 354.4% to $6.27 in pre-market trading after gaining over 7% on Wednesday.</li>
<li>VS MEDIA Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSME#NASDAQ">VSME</a>) gained 165.7% to $5.90 in pre-market trading after jumping around 128% on Wednesday.</li>
<li>Brera Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BREA#NASDAQ">BREA</a>) shares surged 144.1% to $1.70 in pre-market trading.</li>
<li>Molecular Templates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) gained 105% to $0.6672 in pre-market trading. Molecular Templates recently announced it approved the liquidation and wind-up of the company.</li>
<li>1847 Holdings LLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NASDAQ">EFSH</a>) rose 61.3% to $2.71 in pre-market trading after jumping 24% on Wednesday.</li>
<li>Gevo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) shares jumped 36.9% to $3.08 in pre-market trading after the company announced it secured a DOE conditional commitment loan of $1.46 billion for its net-zero 1 sustainable aviation fuel plant in South Dakota.</li>
<li>Klotho Neurosciences, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) climbed 29.9% to $0.7297 in pre-market trading after jumping 15% on Wednesday. Klotho Neurosciences recently tapped Peter Moriarty of Shire Pharma as COO.</li>
<li>Fresh Vine Wine, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VINE#NYSE">VINE</a>) shares rose 22.4% to $0.97 in pre-market trading after gaining around 7% on Wednesday. The company recently announced the acquisition of Adifex.</li>
<li>Calumet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) gained 21.7% to $26.69 in pre-market trading after the company announced its subsidiary, Montana Renewables secured a $1.44 billion conditional commitment from the DOE for renewable fuels and biomass energy facility.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Santech Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STEC#NASDAQ">STEC</a>) shares dipped 38.5% to $1.66 in pre-market trading after jumping around 647% on Wednesday.</li>
<li>180 Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares fell 29.1% to $4.59 in pre-market trading. 180 Life Sciences shares jumped 325% on Wednesday after the company announced it is planning to enter the online gaming industry with its newly acquired gaming technology platform.</li>
<li>Versus Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VS#NASDAQ">VS</a>) fell 29.1% to $2.79 in today's pre-market trading. Versus Systems shares jumped 250% on Wednesday after the company announced a $2.5 million investment and licensing agreement with ASPIS.</li>
<li>Carmell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) fell 25.1% to $0.4710 in pre-market trading. Carmell shares surged around 68% on Wednesday after the company in a FormRW filing disclosed that it decided to not pursue the offering due to business decisions and confirmed that no securities covered by the Registration Statement have been issued or sold and that the SEC did not declare the Registration Statement effective.</li>
<li>Fangdd Network Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) shares declined 22.4% to $1.11 in pre-market trading after jumping 55% on Wednesday. Fangdd Network Group, last week, said it regained compliance status with the Nasdaq regarding its minimum bid price requirement.</li>
<li>Quoin Pharmaceuticals, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) declined 20.2% to $0.6291 in pre-market trading after jumping 56% on Wednesday.</li>
<li>SAIHEAT Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIH#NASDAQ">SAIH</a>) shares fell 19.8% to $0.7570 after jumping 64% on Wednesday.</li>
<li>Gritstone bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares declined 16.6% to $0.0500 in pre-market trading after falling over 12% on Wednesday.</li>
<li>ProQR Therapeutics N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) shares fell 16.2% to $3.37 in pre-market trading after surging 122% on Wednesday.</li>
<li>Lucid Group, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) fell 14.6% to $2.80 in pre-market trading after the company announced a public offering of common stock, along with a corresponding investment by an affiliate of the Public Investment Fund.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41366043/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

ATNF

BREA

CLMT

CTCX

EFSH

GEVO

GRTS

KLTO

MTEM

QNRX

SAIH

STAF

STEC

VINE

VSME

Why TSMC Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

WIIM

Pro QR Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS results.

Earnings

ProQR Therapeutics Q1 2024 GAAP EPS €(0.03) Beats €(0.11) Estimate, Sales €6.305M Miss €11.460M Estimate, €96.2M Cash Position As Of End Of Q2 Providing Runway Into Mid-2026

ProQR Therapeutics NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Massachusetts. &nbsp;
As part of the conference program, Gerard Platenburg, Chief Scientific Officer and Co-Founder, ProQR Therapeutics, will present on June 20, 2024 at 2:00pm ET:

Biotech

General

ProQR Presents Its Axiomer RNA Editing Technology At RNA Editing Summit

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy and maintains $2.5 price target.

Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $2.5 Price Target

HC Wainwright &amp; Co. analyst Andrew Fein reiterates ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy and maintains $5 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $5 Price Target

Guidance

Health Care

ProQR Therapeutics' Cash And Cash Equivalents And Short Term Financial Assets Of €102.7M As Of End Of Q1 Provides Runway Into Mid-2026

ProQR Therapeutics Q1 2024 GAAP EPS €(0.09) Misses €(0.07) Estimate, Sales €4.450M Beat €3.144M Estimate

<ul>
<li>ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer&#x2122; RNA Editing Oligonucleotides</li>
<li>Preclinical proof of concept for the Company's AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT Annual Meeting
<ul>
<li>Management webinar May 9, 2024 at 8:00 am EDT</li>
</ul>
</li>
</ul>
LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced new preclinical data for its proprietary Axiomer&#x2122; RNA editing technology platform, including the first preclinical proof of concept data for its AX-0810 pipeline program for cholestatic diseases targeting NTCP. The data are being presented at a poster session today at the American Society of Gene &amp; Cell Therapy (ASGCT) Annual Meeting, May 7-11, 2024, in Baltimore, Maryland.
"Our Axiomer ADAR RNA editing data at ASGCT show the exciting potential of our technology and for the first time in the field we report proof of target engagement leading to meaningful changes in biomarkers in NHPs," said Gerard Platenburg, Chief Scientific Officer and co-founder, ProQR. "In our AX-0810 program targeting NTCP for cholestatic diseases, we have demonstrated preclinical proof of concept showing that Axiomer RNA editing oligonucleotides can have a meaningful effect on levels of serum biomarker bile acid. We believe this is a significant derisking step as we approach the clinic as our NHP studies closely resemble the design of the first in human trial that will focus on target engagement and biomarkers. We look forward to sharing translational data for our AX-0810 program and to announcing our clinical program candidate later this year, as we progress to enter the clinic in late 2024/early 2025."

ProQR Gives Preclinical Proof Of Concept Data For AX-0810 Axiomer RNA Editing Program Targeting NTCP For Cholestatic Diseases

Events

ProQR Therapeutics To Present On Axiomer RNA Editing At ASGCT 27th Annual Meeting

The company announced it has again successfully defended against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer.
The opposition was filed in June 2021 with the European Patent Office (EPO) by a strawman against ProQR&#39;s granted patent&nbsp;<a href="https://www.globenewswire.com/Tracker?data=2Ct1VlHTN7s9kKLzuYjjceoprNCVAnRgUXOy9TbpbOkved0Wb0LKvKfwvcte2z9f0uiOJYBnah3BwVLHtWsFlh14ptX8M2hNCCt0TV84gUnQybAQSnfAzumrPTbCoa85TdnYF5Bje4KPY3O1eTz0OA==" target="_blank">EP 3 507 366 B1</a>,&nbsp;which relates to editing oligonucleotides that have certain chemical modifications in the base and/or ribose sugar to increase stability and recruit endogenous ADAR to edit the target adenosine. This patent is part of ProQR&#39;s intellectual property estate surrounding its Axiomer RNA editing platform and the current generation of its molecules. The Opposition Division of the EPO held a public hearing on April 17, 2024, and ruled such that ProQR&#39;s strong IP position on chemically modified editing oligonucleotides was maintained.
The patent contains broad platform claims including: &quot;An antisense oligonucleotide (AON) capable of forming a double stranded complex with a target RNA sequence in a cell, preferably a human cell, for the deamination of a target adenosine in the target RNA sequence by an ADAR enzyme present in the cell&hellip;&quot;, which protects ProQR&#39;s proprietary ADAR mediated RNA editing platform Axiomer.
&quot;This decision further supports the confidence we have in the broad scope conferred by our IP estate protecting our proprietary Axiomer ADAR-mediated RNA editing technology platform, and the use of chemically modified oligonucleotides to increase stability and recruit endogenous ADAR to edit the target adenosine,&quot; said Ren&eacute; Beukema, Chief Corporate Development Officer and General Counsel. &quot;Given the importance and value of our IP portfolio, we intend to continue to defend against such challenges and remain confident in our leading position, as we progress our science, platform, and pipeline.&quot;
ProQR invented the use of endogenous ADAR in RNA editing in 2014 and filed a first patent application in that same year.&nbsp;

ProQR Therapeutics Says It Achieved Successful Defense of New Challenge To Its Axiomer IP Portfolio

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy and raises the price target from $2 to $2.5.

Chardan Capital Maintains Buy on ProQR Therapeutics, Raises Price Target to $2.5

ProQR Therapeutics shares are trading higher after the company reported a year-over-year increase in FY23 EPS results.

ProQR Therapeutics' 2023 Cash And Cash Equivalents Of €118.9M Is Expected To Provide Cash Runway Into Mid-2026

Wave stock soars 73% on positive data for RNA editing treatment (update)

Versus Systems, ProQR, and Santech Holdings are the 3 Penny Stocks to watch on October 17, 2024, based on&nbsp;TipRanks' Penny Stock Screener tool....

3 Penny Stocks to Watch Now, 10/17/24

ProQR Therapeutics announces public offering of ordinary shares

ProQR Therapeutics (PRQR) announced that it has commenced an underwritten public offering of its ordinary shares. ProQR intends to use the net proc...

ProQR Therapeutics announces ordinary shares offering, no amount given

ProQR Therapeutics prices $75M offering and enters $12M private placement

In addition, ProQR Therapeutics (PRQR) sold 3.52M shares of common stock to existing shareholder Eli Lilly (LLY). Evercore ISI, Cantor Fitzgerald, ...

ProQR Therapeutics 18M share Spot Secondary priced at $3.50

Latest data shows the largest indicative borrow rate increases among liquid option names include: LASER PHOTONICS CORPORATION (

Largest borrow rate increases among liquid names

ProQR (PRQR) has released an update. ProQR Therapeutics N.V. has entered into an underwriting agreement to sell 18 million ordinary shares with the...

ProQR Announces Major Share Offering Agreement

Raymond James upgraded ProQR Therapeutics (PRQR) to Strong Buy from Outperform with a price target of $14, up from $6. The firm cites the recent su...

ProQR Therapeutics upgraded to Strong Buy from Outperform at Raymond James

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Trade Desk downgraded, First Solar upgraded: Wall Street's top analyst calls

AMZN

BBAI

BLUE

BYND

GOEV

HLIT

KRRO

LASE

MGNI

OMEX

RAMP

RXST

Press Releases

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases

ProQR Announces First Quarter 2024 Operating and Financial Results

ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit

ProQR Announces Second Quarter 2024 Operating and Financial Results

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

Comments

ProQR Therapeutics

Vendite allo scoperto

ProQR Therapeutics (NASDAQ:PRQR) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO